Volume 20 Issue 8
Aug.  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(8): 1302-1306
CHEN Ru-jun, SUN Qian, WANG Geng-ming, JIANG Hao. Survival and prognostic factors of hypofractionated radiation therapy with helical tomotherapy for pulmonary oligometastases[J]. Chinese Journal of General Practice, 2022, 20(8): 1302-1306. doi: 10.16766/j.cnki.issn.1674-4152.002582
Citation: CHEN Ru-jun, SUN Qian, WANG Geng-ming, JIANG Hao. Survival and prognostic factors of hypofractionated radiation therapy with helical tomotherapy for pulmonary oligometastases[J]. Chinese Journal of General Practice, 2022, 20(8): 1302-1306. doi: 10.16766/j.cnki.issn.1674-4152.002582
shu

Survival and prognostic factors of hypofractionated radiation therapy with helical tomotherapy for pulmonary oligometastases

doi: 10.16766/j.cnki.issn.1674-4152.002582

  • Department of Radiation Oncology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 1408085MH190

 KJ2021A0715

 2020b07030008

  • Received Date: 2022-01-02
    Available Online: 2022-09-26
    Abstract
  •   Objective  Helical tomography (HT) has great advantages in protecting the normal tissues and organs around multiple lesions and large tumours and reducing the toxicity of radiotherapy. The aim of this study was to analyse treatment outcomes after hypofractionated stereotactic radiation therapy with HT for pulmonary oligometastases and identify prognostic factors for better survival outcomes.  Methods  The data of 45 patients with lung oligometastases who completed helical tomographic hypofractionation radiotherapy in the Department of tumor radiotherapy, the First Affiliated Hospital of Bengbu Medical College from January 1, 2018 to June, 30, 2021 were retrospectively analyzed. Kaplan-Meier was used to estimate overall survival (OS), local control rate (LCR) and progression-free survival (PFS). The Cox proportional hazards model was used to determine the independent prognostic factors of the patients. Treatment-related toxicity was evaluated using common terminology criteria for adverse events (CTCAE) version 5.0.  Results  Follow-up was performed until September 30, 2021. All patients completed the treatment plan during a median follow-up of 16.0 (12.3, 24.2) months. The median biological effective dose was 76.8 (72.8, 90.0) Gy. The 1-year and 2-year OS rates were 94.8% and 58.1%, respectively. The 1-year and 2-year local control rates were 83.8% and 74.1%, respectively. The 1-year and 2-year PFS rates were 57.8% and 43.3%, respectively. The Karnofsky performance status (KPS)>80 before treatment was significantly associated with better LCR in univariate analysis (P=0.043). Multivariate analysis showed that distant lymph node metastasis before diagnosis of lung metastases was associated with better OS (P=0.041, HR=3.014, 95% CI: 1.043-8.706); 4D computed tomography remained an independent factor significantly associated with better PFS (P=0.035, HR=2.693, 95% CI: 1.072-6.761). No treatment-related deaths and grade≥3 toxicities occurred.  Conclusion  Hypofractionated stereotactic radiation therapy with HT for lung oligometastases is safe and effective. Patients with KPS>80 and no distant lymph node metastasis before diagnosis of lung metastasis has a longer survival time.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    付后卫, 何顺朋, 施祥德, 等. 转移瘤动物模型的构建及其检测方法[J]. 中华全科医学, 2017, 15(1): 142-146. doi: 10.16766/j.cnki.issn.1674-4152.2017.01.043

    FU H W, HE S P, SHI D X, et al. Construction and detection of metastases in animal models[J]. Chinese Journal of General Practice, 2017, 15(1): 142-146. doi: 10.16766/j.cnki.issn.1674-4152.2017.01.043
    [2]
    雷俊琴, 刘文扬, 金晶. 立体定向放疗用于结直肠癌肝与肺寡转移的研究进展[J]. 中华放射肿瘤学杂志, 2021, 30(12): 1316-1320. doi: 10.3760/cma.j.cn113030-20200330-00145

    LEI J Q, LIU W Y, JIN J. Stereotactic body radiation therapy for liver and lung oligometastases from colorectal cancer: safety, local efficacy and prognostic factors[J]. Chinese Journal of Radiation Oncology, 2021, 30(12): 1316-1320. doi: 10.3760/cma.j.cn113030-20200330-00145
    [3]
    ANDRUSKA N, STOWE H B, CROCKETT C, et al. Stereotactic radiation for lung cancer: A practical approach to challenging scenarios[J]. J Thorac Oncol, 2021, 16(7): 1075-1085. doi: 10.1016/j.jtho.2021.04.002
    [4]
    RUERS T, VAN COEVORDEN F, PUNT C J, et al. Local treatment of unresectable colorectal liver metastases: Results of a randomized Phase Ⅱ Trial[J]. J Natl Cancer Inst, 2017, 109(9): djx015. DOI: 10.1093/jnci/djx015.
    [5]
    卢振国, 孙君碟, 向作林, 等. 不可手术切除的肝转移癌行50 Gy/10 f分割模式立体定向放疗疗效评估[J]. 中国临床医学, 2020, 27(6): 1007-1010. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX202006024.htm

    LU Z G, SUN J D, SHI Z L, et al. Stereotactic body radiotherapy with 50 Gy in 10 fractions for unresectable liver metastasis[J]. Chinese Journal Of Clinical Medicine, 2020, 27(6): 1007-1010. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX202006024.htm
    [6]
    巴云涛, 王权, 刘海龙, 等. 大分割放疗治疗早期乳腺癌保乳手术后患者的疗效及安全性[J]. 癌症进展, 2020, 18(4): 384-387. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202004016.htm

    BA Y T, WANG Q, LIU H L, et al. Effect and safety of hypofractionated radiotherapy for early breast cancer patients after breast-conserving surgery[J]. Oncology Progress, 2020, 18(4): 384-387. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202004016.htm
    [7]
    SHARMA A, DUIJM M, OOMEN-DE HOOP E, et al. Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy[J]. Acta Oncol, 2019, 58(1): 74-80. doi: 10.1080/0284186X.2018.1521986
    [8]
    LIU P, LIU G, WANG G, et al. Comparison of dosimetric gains provided by intensity-modulated radiotherapy, volume-modulated arc therapy, and helical tomotherapy for high-grade glioma[J]. Biomed Res Int, 2020, 2020: 4258989. DOI: 10.1155/2020/4258989.
    [9]
    FIGLIA V, MAZZOLA R, CUCCIA F, et al. Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: Report of feasibility by a single-center experience[J]. Radiol Med, 2018, 123(6): 406-414. doi: 10.1007/s11547-018-0858-7
    [10]
    ONO T, NAKAMURA M, HIROSE Y, et al. Estimation of lung tumor position from multiple anatomical features on 4D-CT using multiple regression analysis[J]. J Appl Clin Med Phys, 2017, 18(5): 36-42. doi: 10.1002/acm2.12121
    [11]
    LI G, LIU Y, NIE X. Respiratory-Correlated (RC) vs. Time-Resolved (TR) Four-Dimensional Magnetic Resonance Imaging (4DMRI) for radiotherapy of thoracic and abdominal cancer[J]. Front Oncol, 2019, 9: 1024. doi: 10.3389/fonc.2019.01024
    [12]
    张利伟, 娄志霞, 林琳, 等. 4D-定位CT在胸腹部肿瘤精确放疗中的应用[J]. 影像研究与医学应用, 2019, 3(12): 12-15. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYY201912005.htm

    ZHANG L W, LOU Z X, LIN L, et al. Application of 4D-localized CT in accurate radiotherapy of thoracic and abdominal tumors[J]. Journal of Imaging Research and Medical Applications, 2019, 3(12): 12-15. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYY201912005.htm
    [13]
    ZHONG J, SLEVIN F, SCARSBROOK A F, et al. Salvage reirradiation options for locally recurrent prostate cancer: A systematic review[J]. Front Oncol, 2021, 11: 681448. DOI: 10.3389/fonc.2021.681448.
    [14]
    CAO Y, CHEN H, SAHGAL A, et al. An international pooled analysis of SBRT outcomes to oligometastatic spine and non-spine bone metastases[J]. Radiother Oncol, 2021, 164: 98-103. doi: 10.1016/j.radonc.2021.08.011
    [15]
    YU J, KIM D H, LEE J, et al. Radiofrequency ablation versus stereotactic body radiation therapy in the treatment of colorectal cancer liver metastases[J]. Cancer Res Treat, 2021. DOI: 10.4143/crt.2021.674.
    [16]
    LODEWEGES J E, KLINKENBERG T J, UBBELS J F, et al. Long-term outcome of surgery or stereotactic radiotherapy for lung oligometastases[J]. J Thorac Oncol, 2017, 12(9): 1442-1445. doi: 10.1016/j.jtho.2017.05.015
    [17]
    YAMAMOTO T, NⅡBE Y, MATSUMOTO Y, et al. Analyses of local control and survival after stereotactic body radiotherapy for pulmonary oligometastases from colorectal adenocarcinoma[J]. J Radiat Res, 2020, 61(6): 935-944. doi: 10.1093/jrr/rraa071
    [18]
    YAMAMOTO T, NⅡBE Y, MATSUMOTO Y, et al. Stereotactic body radiotherapy for pulmonary oligometastases from esophageal cancer: Results and prognostic factors[J]. Anticancer Res, 2020, 40(4): 2065-2072. doi: 10.21873/anticanres.14164
    [19]
    LARDINOIS I, DEQUANTER D, LECHIEN J R, et al. Survival and treatment outcome of head and neck cancer patients with pulmonary oligometastases[J]. Clin Otolaryngol, 2021, 46(2): 311-317. doi: 10.1111/coa.13668
    [20]
    SIVA S, BRESSEL M, MAI T, et al. Single-fraction vs multifraction stereotactic ablative body radiotherapy for pulmonary oligometastases (SAFRON Ⅱ): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 randomized cinical trial[J]. JAMA Oncol, 2021, 7(10): 1476-1485. doi: 10.1001/jamaoncol.2021.2939
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (343) PDF downloads(10) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return